News Health Canada Approves KEYTRUDA® (pembrolizumab) for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgeryBy adminApril 18, 20220 Phase 3 KEYNOTE-522 study data-based approval Kirkland, Quebec, April 18, 2022 / CNW /-Merck (NYSE: MRK), known as External MSD…
